Business Context and Reporting Period
Cognition Therapeutics, Inc. (CGTX), an emerging growth company incorporated in Delaware, filed this Form 8-K on August 27, 2025. The filing reports the entry into material definitive agreements regarding a registered direct offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered direct offering of common stock.
- Shares Issued: 14,700,000 shares of Common Stock.
- Purchase Price: $2.05 per share.
- Gross Proceeds: Approximately $30.1 million.
- Placement Agent: Titan Partners Group LLC (division of American Capital Partners, LLC).
- Placement Fees: 7.0% of gross proceeds plus reimbursement of up to $100,000 in expenses.
- Placement Agent Warrants: Warrants to purchase 514,500 shares at an exercise price of $2.78, exercisable after six months with a five-year term.
- Expected Closing Date: On or about August 29, 2025.
Material Changes and Agreements
The Company entered into Securities Purchase Agreements with two institutional investors and a Placement Agency Agreement with Titan. The offering is conducted pursuant to a shelf registration statement (Form S-3) declared effective on January 3, 2023. The filing does not provide comparative financial data (revenue, profit, cash flow, or debt) as this is a current report on a specific transaction rather than a periodic financial statement.
Guidance, Outlook, and Restrictions
- Lock-Up Agreements: The Company, its directors, and executive officers have agreed to a 60-day lock-up period following the closing of the offering, prohibiting the sale or transfer of securities without prior written consent.
- Use of Proceeds: The filing does not specify the intended use of the net proceeds.
- Risks and Contingencies: The agreements include customary representations, warranties, covenants, and indemnification obligations under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement fees and expenses.
- Review the impact of the 14.7 million new shares on existing shareholder dilution.
- Confirm the specific use of proceeds in subsequent filings or press releases.
- Monitor the 60-day lock-up expiration date for potential selling pressure from insiders.
- Examine the Placement Agent Warrants (Exhibit 4.1) for specific terms regarding exercise and potential future dilution.